Inventor · disambiguated record
Marc André Ceusters
Also filed as: CEUSTERS MARC · CEUSTERS MARC ANDRE · Ceusters Marc André
11 granted patents·3 pending applications·26 citations·filing 1995–2024
86Inventor score
Top patents by PatentIndex Score
14 records- 0186US2025288584A1Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their useJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 0285US2025041301A1Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their useJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 0380US9708315B21,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptorsJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Jul 18, 2017·5 cites·5 claims
- 0479US11369606B2Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their useJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Jun 28, 2022·1 cites·20 claims
- 0576US12048696B2Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their useJANSSEN PHARMACEUTICA NV·Filed 2021·Granted Jul 30, 2024·0 cites·24 claims
- 0676US11103506B2Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their useJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Aug 31, 2021·0 cites·14 claims
- 0775US2022143141A1Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their useJANSSEN PHARMACEUTICA NV·Filed 2021·Application pending·0 cites
- 0871US10537573B2Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their useJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Jan 21, 2020·1 cites·20 claims
- 0969US7208503B2Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivativesJANSSEN PHARMACEUTICA NV·Filed 2003·Granted Apr 24, 2007·4 cites·4 claims
- 1062US6833369B2Angiogenesis inhibiting 5-substituted-1,2,4,-thiadiazolyl derivativesJANSSEN PHARMACEUTICA NV·Filed 2001·Granted Dec 21, 2004·2 cites·18 claims
- 1159US6602873B2Angiogenesis inhibiting thiadiazolyl pyridazine derivativesJANSSEN PHARAMACEUTICA N V·Filed 2001·Granted Aug 5, 2003·2 cites·10 claims
- 1241US6194386B1Labelled peptide compoundsMALLINCKRODT INC·Filed 1999·Granted Feb 27, 2001·6 cites·1 claims
- 1335US6265407B1Angiogenesis inhibiting thiadiazolyl pyridazine derivativesJANSSEN PHARMACEUTICA NV·Filed 1998·Granted Jul 24, 2001·1 cites·7 claims
- 1433US5952464ALabelled peptide compoundsMALLINCKRODT INC·Filed 1995·Granted Sep 14, 1999·4 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when Marc André Ceusters files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →